about
European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolidNebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysisNoninvasive ventilation for acute respiratory failure.The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature reviewPassive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study.Predicting treatment failure in patients with community acquired pneumonia: a case-control study.Inflammatory response in mixed viral-bacterial community-acquired pneumoniaDetection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.Characterization of mandibular molar root and canal morphology using cone beam computed tomography and its variability in Belgian and Chilean population samples.Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study.Year in review in Intensive Care Medicine 2013: II. Sedation, invasive and noninvasive ventilation, airways, ARDS, ECMO, family satisfaction, end-of-life care, organ donation, informed consent, safety, hematological issues in critically ill patientsCorticosteroids as adjunctive treatment in community-acquired pneumonia.Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.Pharmacotherapy for hospital-acquired pneumonia.The management of severe community acquired pneumonia in the intensive care unit.New antimicrobial approaches to gram positive respiratory infections.Noninvasive ventilation in withdrawal from mechanical ventilation.The clinical positioning of telavancin in Europe.Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit.Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease.The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients.Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.Impact of COPD in the outcome of ICU-acquired pneumonia with and without previous intubation.Professions and Working Conditions Associated With Community-Acquired Pneumonia.Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted?Severity and outcomes of community acquired pneumonia in asthmatic patients.Pulmonary complications in hematopoietic SCT: a prospective study.Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.Lung ultrasound in the evaluation of pleural effusion.Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013).Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile.Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study.Endotracheal tubes for critically ill patients: an in vivo analysis of associated tracheal injury, mucociliary clearance, and sealing efficacy.
P50
Q26823518-383462F5-C809-4F98-B054-FA7895C54C5BQ28084615-C5F2F1AD-CECD-49D2-9938-301E300C1EB8Q30369493-4C1DAE76-14E0-4597-B9C7-72759C085BA7Q33701151-33840CB0-76A7-4709-A3E9-D18229597765Q33795742-F2708D22-B492-49EB-B331-153DA19B0BCDQ33906338-4755D41E-7477-4527-A82C-AF281BF173E9Q33987876-3CFCD568-DE8B-4C00-B270-5AA3A5F5C9FEQ34512699-2C8B4916-D86B-4389-B054-C37ECD803428Q34798448-496DB7DB-DB5A-496F-8638-E22E43494DA1Q35675040-5D9347FC-6DF5-49D3-8B12-FD4B71804FB9Q35790702-1D3D6359-E67D-499B-90C8-556B47A055D6Q35816268-ED4C8ECC-7ED1-435F-97B8-F86A1A85C889Q35960694-9B056D41-FE3A-4F4F-B3AC-5ABE0BEA4017Q37717451-3097D2BB-B071-4D8E-AB32-CE0B16340A69Q38181385-8C11A7AA-465D-441E-95D1-8BAB5A24C8BDQ38187235-7C234B4B-BBA1-4A7F-9FFD-521A2C1E7FC0Q38187368-EB1DA6ED-D71A-4FCA-B630-879D62B73677Q38192023-3ADCECB7-D3BB-451C-8323-99EEA3FEEE36Q38212536-F8EB4D09-7546-43B4-B776-E842EB5AC618Q38216141-9BBE469E-56AB-49F8-9031-3AB43FB57433Q38238857-C0C64C60-2844-47EA-9802-B4E786ECE832Q38323996-46F609A2-7DFB-4FA3-B69D-D80BEBA2E59DQ38416149-A2137112-87EB-4621-AB0C-26AA6DC01337Q40177316-36081956-FA91-443C-8786-C1F56FFC8901Q40959689-7B18C19F-5623-4B78-A04C-4EB6CD23539EQ40980455-5270BAEE-239A-4A18-A99D-CC2B6E2D18B4Q41164094-2CCAB6A9-E68F-4FEA-AD63-C127D6BEDCDFQ41326027-C5834FD8-FDE3-4742-A10D-AE04A56BC3FFQ41525939-37A3CFD1-1BD6-40FA-9B8E-3237E4ACD8F6Q41528013-1933B315-7B7B-4368-8B99-ED6FECC32A23Q41579148-F02DBFD2-9DEB-4073-B207-12A032CC90F8Q41711114-A63A4E4B-A42F-4889-8F18-3F26319C97E8Q41729752-85E28EB2-929B-4244-AA23-EBE68B6AB046Q42204784-62ED87E0-D96D-4FB2-982E-F9EAA367C786Q42228491-55E9EE16-830D-4A66-8F45-E2D5C5F4EA28Q42715054-459DF764-3C8E-49FA-94F8-3D10629F8B4DQ44139779-1722E919-53BD-400B-89D1-96C8A74235CCQ44189834-2F73D8A4-21C9-4A83-A203-BEB7AEA243D3Q44211958-9DC14B8D-596C-40C4-BBDA-5B2E0829A138Q48693480-AC8F5083-981C-4804-8CF5-E4EE3B86DFB3
P50
description
Spaans onderzoeker
@nl
forsker
@nb
researcher
@en
հետազոտող
@hy
name
A. Torres
@ast
A. Torres
@nl
A. Torres
@sl
Antonio Torres
@en
Antonio Torres
@es
Antonio Torres
@nb
type
label
A. Torres
@ast
A. Torres
@nl
A. Torres
@sl
Antonio Torres
@en
Antonio Torres
@es
Antonio Torres
@nb
altLabel
A. Torres
@en
prefLabel
A. Torres
@ast
A. Torres
@nl
A. Torres
@sl
Antonio Torres
@en
Antonio Torres
@es
Antonio Torres
@nb
P106
P1153
7401785975
P21
P27
P31
P496
0000-0002-8643-2167